Guided Therapeutics (Guided Therapeutics) Change In Working Capital : $0.34 Mil (TTM As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Guided Therapeutics Change In Working Capital?

Guided Therapeutics's change in working capital for the quarter that ended in Mar. 2024 was $0.23 Mil.

Guided Therapeutics's change in working capital for the fiscal year that ended in Dec. 2023 was $-0.11 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Guided Therapeutics Change In Working Capital Historical Data

The historical data trend for Guided Therapeutics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guided Therapeutics Change In Working Capital Chart

Guided Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

1.27

-0.78

0.08

0.55

-0.11

Guided Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-0.21	-0.05	-0.02	0.17	0.23

Guided Therapeutics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.34 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Guided Therapeutics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Guided Therapeutics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Guided Therapeutics (Guided Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guided Therapeutics Inc (OTCPK:GTHP) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092

Website

https://www.guidedinc.com

Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.

Executives

John E Imhoff	director, 10 percent owner	P.O. BOX 31083, SEA ISLAND GA 31561
Alan Grujic	director	349 FORBES AVE, SAN RAFAEL CA 94901
Michael C James	director	2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Richard P. Blumberg	director	2357 HOBART AVENUE S.W., SEATTLE WA 98116
Lynne H Imhoff	10 percent owner	2716 SOUTH ROCKFORD ROAD, TULSA OK 74114
Gene S Cartwright	officer: Chief Executive Officer	4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Parsons & Whittemore Enterprises Corp.	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 10-year Grat	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F Landegger	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573
Whittemore Collection Ltd	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
George F. Landegger 2010 5-year Grat	10 percent owner	4 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Linda Rosenstock	director	5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630
Jonathan M Niloff	director	C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460
Ronald W Allen	director	P O BOX 1734, ATLANTA GA 30301
Shabbir Bakir Bambot	officer: VP of R & D	4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071

Guided Therapeutics (Guided Therapeutics) Headlines

From GuruFocus

Dr. Gene Cartwright, CEO of Guided Therapeutics Joins Everett Jolly on Uptick Newswire's “Stock Day” Podcast to Discuss LuViva® Advanced Cervical Scan

By Marketwired Marketwired • 05-16-2018